BREAKING
Viavi Solutions Stock Jumps 5.3% in Broad Rally 2 hours ago Prologis, Inc. Delivers Q1 Upside: EPS Beats by 82.9%, Revenue Up 7% 3 hours ago MaxLinear, Inc. Jumps 5.4% Amid Sector-Wide Selling 4 hours ago Saia, Inc. Jumps 6.2% 4 hours ago Abbott Laboratories Shares Dropping 5.6% 4 hours ago Manhattan Bridge Capital, Inc. (LOAN) Reports Q1 2026 Earnings 4 hours ago Insteel Industries Inc. Q2: Revenue Hits $172.7M, Up 8% Year-Over-Year 5 hours ago Kaiser Aluminum Corporation (KALU) Jumps 6.2% to $146.69 5 hours ago KeyCorp Posts 10% Revenue Jump in Q1, Beats on EPS 5 hours ago Rxo, Inc. Jumps 5.6% in Broad Selloff 5 hours ago Viavi Solutions Stock Jumps 5.3% in Broad Rally 2 hours ago Prologis, Inc. Delivers Q1 Upside: EPS Beats by 82.9%, Revenue Up 7% 3 hours ago MaxLinear, Inc. Jumps 5.4% Amid Sector-Wide Selling 4 hours ago Saia, Inc. Jumps 6.2% 4 hours ago Abbott Laboratories Shares Dropping 5.6% 4 hours ago Manhattan Bridge Capital, Inc. (LOAN) Reports Q1 2026 Earnings 4 hours ago Insteel Industries Inc. Q2: Revenue Hits $172.7M, Up 8% Year-Over-Year 5 hours ago Kaiser Aluminum Corporation (KALU) Jumps 6.2% to $146.69 5 hours ago KeyCorp Posts 10% Revenue Jump in Q1, Beats on EPS 5 hours ago Rxo, Inc. Jumps 5.6% in Broad Selloff 5 hours ago
ADVERTISEMENT
ALKS

Alkermes plc

$ALKS NASDAQ Feb 12, 2026 BMO FY 2026

Investor Toolbox

Listen to Call

Recording not yet available.

Read Transcript

Transcript not yet available.

View Infographic

Infographic not yet available.

Earnings History

View past quarters and earnings trends.

View History

ALKS Coverage

Event Alkermes plc (ALKS) Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting Apr 16, 2026 Event Alkermes plc (ALKS) Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry Apr 14, 2026 Event Alkermes plc (ALKS) Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2 Apr 1, 2026 Transcript Alkermes plc (ALKS) Q4 2025 Earnings Call Transcript Mar 10, 2026 Transcript Alkermes plc (ALKS) Q2 2025 Earnings Call Transcript Jan 22, 2026 Transcript Alkermes plc (ALKS) Q3 2025 Earnings Call Transcript Jan 22, 2026